Shares of Leap Therapeutics, Inc. nosedived more than 70% to an all-time low on Tuesday, making them the top loser across U.S ...

In this article, Cerba dives into CAR+ T-cell therapy, from patient treatment to solutions for minimal residual disease (MRD) ...

Advancement of next-generation APJ agonists with discontinuation of azelaprag Nomination of NLRP3 inhibitor BGE-102 as a development candidate, with initial Ph1 clinical data anticipated by end of 202 ...

Leap Therapeutics, Inc.'s DKN-01 trial results show mixed outcomes in cancer treatment, prompting potential future funding ...

Newer treatments target pathways like Delta-like ligand 3, poly-ADP-ribose polymerase, and histone deacetylase to address ...

GSK (NYSE:GSK) announced Tuesday that the EU drug regulator has agreed to review depemokimab, an experimental monoclonal antibody targeting a class of cell signaling molecules called interleukin-5, ...

SAB-142 was generally well-tolerated among healthy volunteers; data from Phase 1 trial confirms SAB-142 does not cause serum sickness or ...

Discover the top-performing biotech stocks in 2024! From oncology to psychedelics some companies showed remarkable results.

“We are pleased to welcome Darcy and Emily to Fortis,” said Dave King, CEO of Fortis Life Sciences. “Their exceptional leadership, strategic insight, and extensive industry expertise will further ...

Bispecific antibodies have altered the multiple myeloma (MM) treatment landscape, but some practices still lack enough familiarity with these therapeutics to deliver them in outpatient settings.

In this review of RNA therapies, we paint an overview of what’s going on in a field that is addressing a number of diseases.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.